Atea Pharmaceuticals, Inc.
AVIR
$2.89
$0.020.70%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 52.34% | 51.60% | 55.01% | 45.40% | 6.30% |
| Gross Profit | -52.34% | -51.60% | -55.01% | -45.40% | -6.30% |
| SG&A Expenses | -2.14% | -7.35% | -1.90% | 1.53% | 2.47% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 31.48% | 28.34% | 32.37% | 28.12% | 4.80% |
| Operating Income | -31.48% | -28.34% | -32.37% | -28.12% | -4.80% |
| Income Before Tax | -24.10% | -32.60% | -59.91% | -44.29% | -12.92% |
| Income Tax Expenses | -9.14% | 32.45% | 132.00% | 131.01% | 128.36% |
| Earnings from Continuing Operations | -23.85% | -32.60% | -65.80% | -49.73% | -17.30% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -23.85% | -32.60% | -65.80% | -49.73% | -17.30% |
| EBIT | -31.48% | -28.34% | -32.37% | -28.12% | -4.80% |
| EBITDA | -31.58% | -28.44% | -32.48% | -28.15% | -4.69% |
| EPS Basic | -22.67% | -31.63% | -64.91% | -49.17% | -17.07% |
| Normalized Basic EPS | -42.90% | -34.39% | -33.65% | -20.52% | 10.83% |
| EPS Diluted | -22.67% | -31.63% | -64.91% | -49.17% | -16.73% |
| Normalized Diluted EPS | -42.90% | -34.39% | -33.65% | -20.52% | 10.83% |
| Average Basic Shares Outstanding | 1.05% | 0.78% | 0.52% | 0.30% | 0.18% |
| Average Diluted Shares Outstanding | 1.05% | 0.78% | 0.52% | 0.30% | 0.18% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |